Reading time: 4 minutes Chris Wang Unlike the Merriam Webster definition of promiscuous, describing a kinase inhibitor as promiscuous actually refers to the number of kinases it inhibits. The more promiscuous an inhibitor is, the higher number of off-targets it has. Traditional drug development strategies avoid promiscuous compounds because off-target effects can lead to side... Continue Reading →
How cancer cells dodge targeted “silver bullet” treatments: BRAF/MEK resistance in melanoma
Reading time: 5 minutes Chris Wang Like Keanu Reeves dodging bullets within The Matrix, cancer cells can dodge even carefully designed anti-cancer agents. Scientists strive to design “silver bullets,” ones which target cancer cells while sparing healthy normal cells. This "silver bullet" approach is appealing to researchers due to the promise of improved therapeutic response... Continue Reading →
CDK4/6 Kinase Inhibitors: Limiting Chemotherapy Toxicity
Reading time: 5 minutes Chris Wang Chemotherapy is a mainstay of cancer treatment, yet many times it is temporarily withheld or stopped due to significant toxicity. This is because chemotherapy drugs cannot differentiate between killing cancer cells and killing fast growing healthy cells, such as cells in your bone marrow. These cells divide quickly because... Continue Reading →